Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Why Lilly and Boehringer Backed a German Startup’s mRNA ‘on-Off Switch’ in a €31.5M Seed

Summary by Tech Funding News
SRTD Biotech raises €31.5M led by Mérieux Equity Partners to develop selectively expressed RNA therapies for cancer, viral and autoimmune diseases.

4 Articles

wz.dewz.de
Reposted by
bbv-net.debbv-net.de
Center

NRW-Bank Participates in Biotech Start-Up

The NRW-Bank invests seven million euros in the Jülich company SRTD Biotech. It develops active ingredients that are specifically intended to be used in sick cells. How does this work?

Read Full Article
HandelsblattHandelsblatt
Lean Right

Start-up: This German Start-up Wants to Become the Next mRNA Pioneer

In one of the largest European biotech seed rounds SRTD collects 31.5 million euros. The main investor sees synergies with Biontech. This is not only of medical importance.

·Düsseldorf, Germany
Read Full Article
Tech Funding NewsTech Funding News

Why Lilly and Boehringer backed a German startup’s mRNA ‘on-off switch’ in a €31.5M seed

SRTD Biotech raises €31.5M led by Mérieux Equity Partners to develop selectively expressed RNA therapies for cancer, viral and autoimmune diseases.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources are Center, 50% of the sources lean Right
50% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Handelsblatt broke the news in Düsseldorf, Germany on Monday, November 9, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Cancer icon

Cancer

Startups icon

Startups

Germany icon

Germany

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal